Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database
Carregando...
Citações na Scopus
254
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMJ PUBLISHING GROUP
Autores
MEIER, Florian M. P.
FROMMER, Klaus W.
DINSER, Robert
WALKER, Ulrich A.
CZIRJAK, Laszlo
DENTON, Christopher P.
ALLANORE, Yannick
DISTLER, Oliver
RIEMEKASTEN, Gabriela
VALENTINI, Gabriele
Citação
ANNALS OF THE RHEUMATIC DISEASES, v.71, n.8, p.1355-1360, 2012
Resumo
Objectives Systemic sclerosis (SSc) is a rare disease requiring multicentre collaboration to reveal comprehensive details of disease-related causes for morbidity and mortality. Methods The European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) group initiated a database to prospectively gather key data of patients with SSc using a minimal essential dataset that was reorganised in 2008 introducing new items. Baseline visit data of patients who were registered between 2004 and 2011 were analysed using descriptive statistics. Results In June 2011, 7655 patients (2838 with diffuse cutaneous (dc) and 4481 with limited cutaneous (lc) SSc who fulfilled the American College of Rheumatology diagnostic criteria had been registered in 174 centres, mainly European. The most prominent hallmarks of disease were Raynaud's phenomenon (96.3%), antinuclear antibodies (93.4%) and a typical capillaroscopic pattern (90.9%). Scleroderma was more common on fingers and hands than on any other part of the skin. Proton pump inhibitors (65.2%), calcium channel blockers (52.7%), and corticosteroids (45.3%) were most often prescribed. Among the immunosuppressant agents, cyclophosphamide was used more often in dcSSc than in lcSSc. Conclusions The EUSTAR database provides an abundance of information on the true clinical face of SSc that will be helpful in improving the classification of SSc and its subsets and for developing more specific therapeutic recommendations.
Palavras-chave
Referências
- [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581
- Avouac J, 2011, ANN RHEUM DIS, V70, P476, DOI 10.1136/ard.2010.136929
- Avouac J, 2010, J RHEUMATOL, V37, P2290, DOI 10.3899/jrheum.100245
- Beyer C, 2011, ANN RHEUM DIS, V70, P1178, DOI 10.1136/ard.2010.142489
- Cutolo M, 2004, RHEUMATOLOGY, V43, P719, DOI 10.1093/rheumatology/keh156
- Galie N, 2009, EUR HEART J, V30, P2493, DOI 10.1093/eurheartj/ehp297
- Hunzelmann N, 2008, RHEUMATOLOGY, V47, P1185, DOI 10.1093/rheumatology/ken179
- Hunzelmann N, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2634
- Kowal-Bielecka O, 2009, ANN RHEUM DIS, V68, P620, DOI 10.1136/ard.2008.096677
- La Montagna G, 2005, SKELETAL RADIOL, V34, P35, DOI 10.1007/s00256-004-0830-6
- LeRoy EC, 2001, J RHEUMATOL, V28, P1573
- LUNDBERG AC, 1992, ANN RHEUM DIS, V51, P1143, DOI 10.1136/ard.51.10.1143
- Manetti M, 2007, ARTHRITIS RHEUM-US, V56, P3442, DOI 10.1002/art.22940
- Mayes MD, 2003, ARTHRITIS RHEUM, V48, P2246, DOI 10.1002/art.11073
- SHARP GC, 1972, AM J MED, V52, P148, DOI 10.1016/0002-9343(72)90064-2
- Steen VD, 2007, ANN RHEUM DIS, V66, P940, DOI 10.1136/ard.2006.066068
- Tyndall A, 2005, Ann Rheum Dis, V64, P1107, DOI 10.1136/ard.2005.036038
- Valentini G, 2001, ANN RHEUM DIS, V60, P592, DOI 10.1136/ard.60.6.592
- Walker UA, 2007, ANN RHEUM DIS, V66, P754, DOI 10.1136/ard.2006.062901